C-2799 Capecitabine, >99%

Synonyms : [Capecitabin] [Ro 09-1978]

Related Terms : [Capecitibine] [Capecytabine] [Capiibine] [Captabin] [Caxeta] [Xabine] [Xeloda]

  • Size
  • US $
  • £
  • ¥
  • 1 g
  • 46
  • 42
  • 35
  • 7,300
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 84
  • 77
  • 64
  • 13,300
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 155
  • 142
  • 119
  • 24,500
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 270
  • 247
  • 208
  • 42,700
  • Add to Cart Qty:
  • In stock
  • 25 g
  • 645
  • 592
  • 497
  • 102,000
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 359.35
  • C15H22FN3O6
  • [154361-50-9]
  • M.I. 14: 1754

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 12.5 mg/mL with slight warming; soluble in water at 2 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Capecitabine is a pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5'-deoxy-5-fluorocytidine (5'-DFCR), which happens mainly in the liver by carboxyl-esterase. The metabolite is converted to 5'-deoxy-5-fluoro-uridine (5'-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5'-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Miwa, M., et al. "Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue." Eur. J. Cancer 34: 1274-1281 (1998).
  • Capecitabine inhibits tumor growth by incorporation of 5-FU into RNA and DNA and inhibition of thymidylate synthase. Schellens, J.H. "Capecitabine." Oncologist 12: 152-155 (2007).
  • Other CAS numbers previously assigned to capecitabine, 158798-73-3 and 958887-39-3, have been deleted by CAS and are no longer in use.
  • Capecitabine is the active ingredient in the drug products sold under numerous trade names, such as those listed near the top of this page as "Related Terms".  This drug has been approved in at least one country for use in patients with metastatic breast and colorectal cancers.  NOTE: THE CAPECITABINE SOLD BY LC LABORATORIES FOR RESEARCH IS NOT ANY OF THE CAPECITABINE -CONTAINING DRUG PRODUCTS SOLD UNDER VARIOUS TRADE NAMES AND IS NOT FOR HUMAN USE.

  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries
  • Not available in some countries; not available to some institutions; not available for some uses.